CA2737447A1 - "hayley's comet" - Google Patents

"hayley's comet" Download PDF

Info

Publication number
CA2737447A1
CA2737447A1 CA 2737447 CA2737447A CA2737447A1 CA 2737447 A1 CA2737447 A1 CA 2737447A1 CA 2737447 CA2737447 CA 2737447 CA 2737447 A CA2737447 A CA 2737447A CA 2737447 A1 CA2737447 A1 CA 2737447A1
Authority
CA
Canada
Prior art keywords
cultivar
cbd
cannabinoid
cannabidiolic acid
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2737447
Other languages
English (en)
Inventor
Antony Paul Hornby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2737447 priority Critical patent/CA2737447A1/fr
Publication of CA2737447A1 publication Critical patent/CA2737447A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
CA 2737447 2011-04-27 2011-04-27 "hayley's comet" Abandoned CA2737447A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2737447 CA2737447A1 (fr) 2011-04-27 2011-04-27 "hayley's comet"

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2737447 CA2737447A1 (fr) 2011-04-27 2011-04-27 "hayley's comet"

Publications (1)

Publication Number Publication Date
CA2737447A1 true CA2737447A1 (fr) 2012-10-27

Family

ID=47070977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2737447 Abandoned CA2737447A1 (fr) 2011-04-27 2011-04-27 "hayley's comet"

Country Status (1)

Country Link
CA (1) CA2737447A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10092525B2 (en) 2014-10-14 2018-10-09 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10583096B2 (en) 2016-03-31 2020-03-10 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10603288B2 (en) 2014-06-17 2020-03-31 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10709671B2 (en) 2015-06-17 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10729665B2 (en) 2011-09-29 2020-08-04 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10765643B2 (en) 2014-10-14 2020-09-08 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10918608B2 (en) 2014-10-14 2021-02-16 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11065227B2 (en) 2016-08-25 2021-07-20 GW Research Limited Use of cannabinoids in the treatment of multiple myeloma
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11229612B2 (en) 2016-07-01 2022-01-25 GW Research Limited Parenteral formulations
US11291631B2 (en) 2016-07-01 2022-04-05 GW Research Limited Oral cannabinoid formulations
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US11679087B2 (en) 2016-12-16 2023-06-20 GW Research Limited Use of cannabinoids in the treatment of Angelman syndrome
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729665B2 (en) 2011-09-29 2020-08-04 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11318109B2 (en) 2011-09-29 2022-05-03 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11963937B2 (en) 2014-06-17 2024-04-23 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11766411B2 (en) 2014-06-17 2023-09-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11701330B2 (en) 2014-06-17 2023-07-18 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10603288B2 (en) 2014-06-17 2020-03-31 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11311498B2 (en) 2014-06-17 2022-04-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11154516B2 (en) 2014-06-17 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10765643B2 (en) 2014-10-14 2020-09-08 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11096905B2 (en) 2014-10-14 2021-08-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10092525B2 (en) 2014-10-14 2018-10-09 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10849860B2 (en) 2014-10-14 2020-12-01 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10111840B2 (en) 2014-10-14 2018-10-30 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10918608B2 (en) 2014-10-14 2021-02-16 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10966939B2 (en) 2014-10-14 2021-04-06 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10137095B2 (en) 2014-10-14 2018-11-27 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11065209B2 (en) 2014-10-14 2021-07-20 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10709673B2 (en) 2014-10-14 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11633369B2 (en) 2014-10-14 2023-04-25 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11154517B2 (en) 2014-10-14 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10709674B2 (en) 2014-10-14 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11446258B2 (en) 2014-10-14 2022-09-20 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11400055B2 (en) 2014-10-14 2022-08-02 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10709671B2 (en) 2015-06-17 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11357741B2 (en) 2015-06-17 2022-06-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
AU2016305545B2 (en) * 2015-08-10 2021-12-09 GW Research Limited Use of cannabinoids in the treatment of epilepsy
EP3769755A1 (fr) 2015-08-10 2021-01-27 GW Research Limited Utilisation de l acide cannabidiolique dans le traitement de l'épilepsie
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US11147783B2 (en) 2015-08-10 2021-10-19 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11684598B2 (en) 2015-08-10 2023-06-27 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10583096B2 (en) 2016-03-31 2020-03-10 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11229612B2 (en) 2016-07-01 2022-01-25 GW Research Limited Parenteral formulations
US11291631B2 (en) 2016-07-01 2022-04-05 GW Research Limited Oral cannabinoid formulations
US11065227B2 (en) 2016-08-25 2021-07-20 GW Research Limited Use of cannabinoids in the treatment of multiple myeloma
US11679087B2 (en) 2016-12-16 2023-06-20 GW Research Limited Use of cannabinoids in the treatment of Angelman syndrome
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11406623B2 (en) 2020-02-27 2022-08-09 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Similar Documents

Publication Publication Date Title
CA2737447A1 (fr) "hayley's comet"
CA2859934A1 (fr) Comete de hayley ii
Talsma et al. Biofortified yellow cassava and vitamin A status of Kenyan children: a randomized controlled trial
Dimopoulos et al. Drought stress modulates cuticular wax composition of the grape berry
Cazarin et al. Intestinal anti-inflammatory effects of Passiflora edulis peel in the dextran sodium sulphate model of mouse colitis
US10441617B2 (en) Breeding, production, processing and use of medical cannabis
Gao et al. Selenium deficiency induced an inflammatory response by the HSP60-TLR2-MAPKs signalling pathway in the liver of carp
Fantini et al. Forest structure and productivity of palmiteiro (Euterpe edulis Martius) in the Brazilian Mata Atlântica
Gao et al. Supplementation of xanthophylls decreased proinflammatory and increased anti-inflammatory cytokines in hens and chicks
Dowell et al. Genome-wide association mapping of floral traits in cultivated sunflower (Helianthus annuus)
Wang et al. Application of exogenous auxin and gibberellin regulates the bolting of lettuce (Lactuca sativa L.)
Kar et al. Micropropagation, genetic fidelity assessment and phytochemical studies of Clerodendrum thomsoniae Balf. f. with special reference to its anti-stress properties
CN106172520A (zh) 驱蚊水
CN105230410A (zh) 一种防治甘蔗梢腐病的方法
de Oliveira Prudente et al. Goji berry (Lycium barbarum L.) in vitro multiplication improved by light-emitting diodes (LEDs) and 6-benzylaminopurine
US7838742B2 (en) Pepper plants having fruit with altered vitamin content
Jian et al. Characterization of anthocyanin accumulation, nutritional properties, and postharvest attributes of transgenic purple tomato
Panjeshahin et al. Genetic and Morphological Diversity of Wild Mint
WO2016174600A1 (fr) Compositions à base de bêta-cryptoxanthine, ses procédés de préparation et ses utilisations
CN106069786B (zh) 一种在桉树组织培养中抗褐化和促进不定芽分化的方法
US11240978B2 (en) Hemp variety NBS CBD-1
Aicha et al. Rapid in vitro regeneration and clonal multiplication of Thymus bleicherianus pomel, a rare and threatened medicinal and aromatic plant in Morocco
CN107156037A (zh) 一种肉兔规模化集约化工厂化母兔配种繁育光照控制
Prithvi Raje Urs et al. Evaluation of mulberry (Morus spp.) genotypes for tolerance to major abiotic stresses
TWI702959B (zh) 開發黃花蟛蜞菊的標準化與功效最佳化的草藥抽出物以及其用於治療疾病的用途

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20140429